Combination of Cladribine plus Topotecan for Relapsed or Refractory Pediatric Acute Myeloid Leukemia

BACKGROUND: The prognosis after relapse of pediatric acute myeloid leukemia (AML) is poor and effective salvage regimens are urgently needed. METHODS: In Phase I and pilot studies, we evaluated the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of a 5-day course of cladribine (2-CD...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Inaba, Hiroto, Stewart, Clinton F., Crews, Kristine R., Yang, Shengping, Pounds, Stanley, Pui, Ching-Hon, Rubnitz, Jeffrey E., Razzouk, Bassem I., Ribeiro, Raul C.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2010
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2920745/
https://ncbi.nlm.nih.gov/pubmed/19885837
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.24712
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia